Bone as an endocrine organ

Trends in Endocrinology and Metabolism

Volumn 20, Issue 5, 2009, Pages 230-236

  Fukumoto, Seiji ^a   Martin, T John ^b  

^a UNIVERSITY OF TOKYO HOSPITAL   (Japan)

^b UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIDIOL 1 MONOOXYGENASE; FIBROBLAST GROWTH FACTOR 23; FIBROBLAST GROWTH FACTOR RECEPTOR; GLUCOSE; INSULIN; LEPTIN; OSTEOCALCIN; PHOSPHORUS; VITAMIN D;

AUTOSOMAL DOMINANT HYPOPHOSPHATEMIC RICKETS; BONE; DIABETES MELLITUS; ENDOCRINE FUNCTION; ENERGY METABOLISM; GENE MUTATION; GENE OVEREXPRESSION; GLUCOSE UTILIZATION; HUMAN; INSULIN SENSITIVITY; INSULIN SYNTHESIS; NONHUMAN; ONCOGENIC OSTEOMALACIA; OSTEOCYTE; PANCREAS ISLET BETA CELL; PHOSPHATE METABOLISM; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; REVIEW; X LINKED HYPOPHOSPHATEMIC RICKETS;

ANIMALS; BONE AND BONES; FIBROBLAST GROWTH FACTORS; HUMANS; INSULIN; MODELS, BIOLOGICAL; OSTEOCALCIN; VITAMIN D;

EID: 67649227047     PISSN: 10432760     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tem.2009.02.001     Document Type: Review

References (66)

1. Ducy P., et al. Leptin inhibits bone formation through a hypothalamic relay: a central control of bone mass. Cell 100 (2000) 197-207
2. Karsenty G. Convergence between bone and energy homeostases: leptin regulation of bone mass. Cell Metab. 4 (2006) 341-348
3. Shimada T., et al. FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis. J. Bone Miner. Res. 19 (2004) 429-435
4. Shimada T., et al. Vitamin D receptor-independent FGF23 actions in regulating phosphate and vitamin D metabolism. Am. J. Physiol. Renal Physiol. 289 (2005) F1088-F1095
5. Yamashita T., et al. Identification of a novel fibroblast growth factor, FGF-23, preferentially expressed in the ventrolateral thalamic nucleus of the brain. Biochem. Biophys. Res. Commun. 277 (2000) 494-498
6. ADHR Consortium. Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23. Nat. Genet. 26 (2000) 345-348
7. Shimada T., et al. Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia. Proc. Natl. Acad. Sci. U. S. A. 98 (2001) 6500-6505
8. Fukumoto S., and Yamashita T. FGF23 is a hormone-regulating phosphate metabolism-unique biological characteristics of FGF23. Bone 40 (2007) 1190-1195
9. Miyamoto K., et al. New aspect of renal phosphate reabsorption: the type IIc sodium-dependent phosphate transporter. Am. J. Nephrol. 27 (2007) 503-515
10. Segawa H., et al. Effect of hydrolysis-resistant FGF23-R179Q on dietary phosphate regulation of the renal type-II Na/Pi transporter. Pflugers Arch. 446 (2003) 585-592
11. Shimada T., et al. Targeted ablation of Fgf23 demonstrates an essential physiological role of FGF23 in phosphate and vitamin D metabolism. J. Clin. Invest. 113 (2004) 561-568
12. Sitara D., et al. Homozygous ablation of fibroblast growth factor-23 results in hyperphosphatemia and impaired skeletogenesis, and reverses hypophosphatemia in Phex-deficient mice. Matrix Biol. 23 (2004) 421-432
13. 3 24-hydroxylase gene. J. Biol. Chem. 269 (1994) 10545-10550
14. Riminucci M., et al. FGF-23 in fibrous dysplasia of bone and its relationship to renal phosphate wasting. J. Clin. Invest. 112 (2003) 683-692
15. Feng J.Q., et al. Loss of DMP1 causes rickets and osteomalacia and identifies a role for osteocytes in mineral metabolism. Nat. Genet. 38 (2006) 1310-1315
16. Liu S., et al. Pathogenic role of Fgf23 in Hyp mice. Am. J. Physiol. Endocrinol. Metab. 291 (2006) E38-E49
17. Mirams M., et al. Bone as a source of FGF23: regulation by phosphate?. Bone 35 (2004) 1192-1199
18. Yoshiko Y., et al. Mineralized tissue cells are a principal source of FGF23. Bone 40 (2007) 1565-1573
19. Jonsson K.B., et al. Fibroblast growth factor 23 in oncogenic osteomalacia and X-linked hypophosphatemia. N. Engl. J. Med. 348 (2003) 1656-1663
20. Yamazaki Y., et al. Increased circulatory level of biologically active full-length FGF-23 in patients with hypophosphatemic rickets/osteomalacia. J. Clin. Endocrinol. Metab. 87 (2002) 4957-4960
21. Takeuchi Y., et al. Venous sampling for fibroblast growth factor-23 confirms preoperative diagnosis of tumor-induced osteomalacia. J. Clin. Endocrinol. Metab. 89 (2004) 3979-3982
22. Ferrari S.L., et al. Fibroblast growth factor-23 relationship to dietary phosphate and renal phosphate handling in healthy young men. J. Clin. Endocrinol. Metab. 90 (2005) 1519-1524
23. Saito H., et al. Circulating FGF-23 is regulated by 1alpha,25-dihydroxyvitamin D3 and phosphorus in vivo. J. Biol. Chem. 280 (2005) 2543-2549
24. Powers C.J., et al. Fibroblast growth factors, their receptors and signaling. Endocr. Relat. Cancer 7 (2000) 165-197
25. Goetz R., et al. Molecular insights into the klotho-dependent, endocrine mode of action of fibroblast growth factor 19 subfamily members. Mol. Cell. Biol. 27 (2007) 3417-3428
26. Urakawa I., et al. Klotho converts canonical FGF receptor into a specific receptor for FGF23. Nature 444 (2006) 770-774
27. Kuro-o M., et al. Mutation of the mouse klotho gene leads to a syndrome resembling ageing. Nature 390 (1997) 45-51
28. Kurosu H., et al. Regulation of fibroblast growth factor-23 signaling by klotho. J. Biol. Chem. 281 (2006) 6120-6123
29. Benet-Pages A., et al. FGF23 is processed by proprotein convertases but not by PHEX. Bone 35 (2004) 455-462
30. Shimada T., et al. Mutant FGF-23 responsible for autosomal dominant hypophosphatemic rickets is resistant to proteolytic cleavage and causes hypophosphatemia in vivo. Endocrinology 143 (2002) 3179-3182
31. White K.E., et al. Autosomal-dominant hypophosphatemic rickets (ADHR) mutations stabilize FGF-23. Kidney Int. 60 (2001) 2079-2086
32. Imel E.A., et al. FGF23 concentrations vary with disease status in autosomal dominant hypophosphatemic rickets. J. Bone Miner. Res. 22 (2007) 520-526
33. The HYP Consortium. A gene (PEX) with homologies to endopeptidases is mutated in patients with X-linked hypophosphatemic rickets. Nat. Genet. 11 (1995) 130-136
34. Beck L., et al. Pex/PEX tissue distribution and evidence for a deletion in the 3′ region of the Pex gene in X-linked hypophosphatemic mice. J. Clin. Invest. 99 (1997) 1200-1209
35. Yuan B., et al. Aberrant Phex function in osteoblasts and osteocytes alone underlies murine X-linked hypophosphatemia. J. Clin. Invest. 118 (2008) 722-734
36. Lorenz-Depiereux B., et al. DMP1 mutations in autosomal recessive hypophosphatemia implicate a bone matrix protein in the regulation of phosphate homeostasis. Nat. Genet. 38 (2006) 1248-1250
37. Bonewald L.F. Osteocyte messages from a bony tomb. Cell Metab. 5 (2007) 410-411
38. van Bezooijen R.L., et al. SOST/sclerostin, an osteocyte-derived negative regulator of bone formation. Cytokine Growth Factor Rev. 16 (2005) 319-327
39. Berndt T., et al. Secreted frizzled-related protein 4 is a potent tumor-derived phosphaturic agent. J. Clin. Invest. 112 (2003) 785-794
40. Carpenter T.O., et al. Fibroblast growth factor 7: an inhibitor of phosphate transport derived from oncogenic osteomalacia-causing tumors. J. Clin. Endocrinol. Metab. 90 (2005) 1012-1020
41. Rowe P.S., et al. MEPE has the properties of an osteoblastic phosphatonin and minhibin. Bone 34 (2004) 303-319
42. Lyles K.W., et al. Correlations of serum concentrations of 1,25-dihydroxyvitamin D, phosphorus, and parathyroid hormone in tumoral calcinosis. J. Clin. Endocrinol. Metab. 67 (1988) 88-92
43. Benet-Pages A., et al. An FGF23 missense mutation causes familial tumoral calcinosis with hyperphosphatemia. Hum. Mol. Genet. 14 (2005) 385-390
44. Ichikawa S., et al. A homozygous missense mutation in human KLOTHO causes severe tumoral calcinosis. J. Clin. Invest. 117 (2007) 2684-2691
45. Topaz O., et al. Mutations in GALNT3, encoding a protein involved in O-linked glycosylation, cause familial tumoral calcinosis. Nat. Genet. 36 (2004) 579-581
46. Frishberg Y., et al. Hyperostosis-hyperphosphatemia syndrome: a congenital disorder of O-glycosylation associated with augmented processing of fibroblast growth factor 23. J. Bone Miner. Res. 22 (2007) 235-242
47. Kato K., et al. Polypeptide GalNAc-transferase T3 and familial tumoral calcinosis. Secretion of fibroblast growth factor 23 requires O-glycosylation. J. Biol. Chem. 281 (2006) 18370-18377
48. Ito N., et al. Comparison of two assays for fibroblast growth factor (FGF)-23. J. Bone Miner. Metab. 23 (2005) 435-440
49. Araya K., et al. A novel mutation in fibroblast growth factor 23 gene as a cause of tumoral calcinosis. J. Clin. Endocrinol. Metab. 90 (2005) 5523-5527
50. +/phosphate cotransporter NaPi-IIa is internalized via the receptor-mediated endocytic route in response to parathyroid hormone. Kidney Int. 69 (2006) 495-503
51. Ben-Dov I.Z., et al. The parathyroid is a target organ for FGF23 in rats. J. Clin. Invest. 117 (2007) 4003-4008
52. Krajisnik T., et al. Fibroblast growth factor-23 regulates parathyroid hormone and 1alpha-hydroxylase expression in cultured bovine parathyroid cells. J. Endocrinol. 195 (2007) 125-131
53. Imura A., et al. α-Klotho as a regulator of calcium homeostasis. Science 316 (2007) 1615-1618
54. Lee N.K., et al. Endocrine regulation of energy metabolism by the skeleton. Cell 130 (2007) 456-469
55. Lee N.K., and Karsenty G. Reciprocal regulation of bone and energy metabolism. Trends Endocrinol. Metab. 19 (2008) 161-166
56. Hauschka P.V., et al. Osteocalcin and matrix Gla protein: vitamin K-dependent proteins in bone. Physiol. Rev. 69 (1989) 990-1047
57. Ducy P., et al. Increased bone formation in osteocalcin-deficient mice. Nature 382 (1996) 448-452
58. Morrison D.F., and Mauro L.J. Structural characterization and chromosomal localization of the mouse cDNA and gene encoding the bone tyrosine phosphatase, mOST-PTP. Gene 257 (2000) 195-208
59. Ferron M., et al. Osteocalcin differentially regulates beta cell and adipocyte gene expression and affects the development of metabolic diseases in wild-type mice. Proc. Natl. Acad. Sci. U. S. A. 105 (2008) 5266-5270
60. Shi Y., et al. Dissociation of the neuronal regulation of bone mass and energy metabolism by leptin in vivo. Proc. Natl. Acad. Sci. U. S. A. 105 (2008) 20529-20533
61. Hinoi E., et al. The sympathetic tone mediates leptin's inhibition of insulin secretion by modulating osteocalcin bioactivity. J. Cell Biol. 183 (2008) 1235-1242
62. Kindblom J.M., et al. Plasma osteocalcin is inversely related to fat mass and plasma glucose in elderly Swedish men. J. Bone Miner. Res. 24 (2009) 785-791
63. Pittas A.G., et al. Association between serum osteocalcin and markers of metabolic phenotype. J. Clin. Endocrinol. Metab. 94 (2009) 827-832
64. Im J.A., et al. Relationship between osteocalcin and glucose metabolism in postmenopausal women. Clin. Chim. Acta 396 (2008) 66-69
65. Fernandez-Real J.M., et al. The relationship of serum osteocalcin concentration to insulin secretion, sensitivity, and disposal with hypocaloric diet and resistance training. J. Clin. Endocrinol. Metab. 94 (2009) 237-245
66. van Bezooijen R.L., et al. Sclerostin is an osteocyte-expressed negative regulator of bone formation, but not a classical BMP antagonist. J. Exp. Med. 199 (2004) 805-814